LRT Capital Management LLC increased its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 37.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,421 shares of the healthcare company's stock after purchasing an additional 20,461 shares during the quarter. LRT Capital Management LLC owned approximately 0.11% of InMode worth $1,243,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in INMD. Harvey Capital Management Inc. grew its holdings in shares of InMode by 1.4% during the 4th quarter. Harvey Capital Management Inc. now owns 51,490 shares of the healthcare company's stock worth $860,000 after purchasing an additional 700 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of InMode by 6.1% during the fourth quarter. Thrivent Financial for Lutherans now owns 12,586 shares of the healthcare company's stock worth $210,000 after acquiring an additional 721 shares during the last quarter. Covestor Ltd boosted its holdings in InMode by 13.9% in the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock valued at $99,000 after acquiring an additional 723 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after buying an additional 1,154 shares during the period. Finally, Invesco Ltd. increased its holdings in InMode by 1.5% in the fourth quarter. Invesco Ltd. now owns 97,475 shares of the healthcare company's stock worth $1,628,000 after purchasing an additional 1,444 shares in the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have commented on INMD. Jefferies Financial Group decreased their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating for the company in a research note on Monday, April 14th. Robert W. Baird downgraded shares of InMode from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $22.00 to $16.00 in a report on Monday, April 28th. BTIG Research lowered shares of InMode from a "buy" rating to a "neutral" rating in a research report on Tuesday, April 29th. UBS Group lowered their price target on InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Finally, Canaccord Genuity Group lowered their price target on shares of InMode from $17.00 to $15.00 and set a "hold" rating for the company in a research note on Tuesday, April 29th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, InMode has an average rating of "Hold" and an average target price of $18.54.
Check Out Our Latest Stock Report on InMode
InMode Price Performance
INMD stock traded up $0.14 during trading on Thursday, reaching $14.71. The company had a trading volume of 1,082,846 shares, compared to its average volume of 1,187,966. The company has a market cap of $1.02 billion, a P/E ratio of 6.26 and a beta of 2.02. The business has a 50 day moving average of $16.17 and a 200 day moving average of $17.38. InMode Ltd. has a 52 week low of $13.68 and a 52 week high of $19.85.
InMode (NASDAQ:INMD - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The firm had revenue of $77.87 million for the quarter, compared to the consensus estimate of $82.21 million. During the same quarter in the prior year, the business posted $0.32 earnings per share. The firm's revenue for the quarter was down 3.0% compared to the same quarter last year. Research analysts expect that InMode Ltd. will post 1.75 earnings per share for the current year.
About InMode
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Further Reading
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
